Sarepta is paying Arrowhead $500 million cash, plus an $325 million equity investment, for worldwide licensing rights to seven programs.

In return, Arrowhead will receive $825 million upfront, comprising $500 million in cash and $325 million in equity at a 35% premium. An additional $250 million will be paid in installments over ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta's purchase of Arrowhead common stock at $27.25 per share.

Arrowhead (ARWR) announced a global licensing and collaboration agreement with Sarepta (SRPT). Upon closing, Arrowhead will receive $825M, consisting of $500M cash and $325M as an equity ...

A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and another $325 million in equity investment.

Sarepta’s new clinical programs from Arrowhead aim to treat facioscapulohumeral muscular dystrophy, myotonic dystrophy type 1, idiopathic pulmonary fibrosis and spinocerebellar ataxia 2.

Sarepta Therapeutics said it will pay Arrowhead Pharmaceuticals $500 million in cash for a series of experimental RNA-based drugs to treat rare diseases.

Sarepta Therapeutics has entered a global licensing and collaboration agreement with Arrowhead Pharmaceuticals to develop RNA interference (RNAi)-based treatments for rare genetic diseases affecting ...

Sarepta Therapeutics (SRPT), the leader in precision genetic medicine for rare diseases announced an exclusive global licensing and collaboration agreement with Arrowhead (ARWR) Pharmaceuticals ...

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta's purchase of Arrowhead common stock at $27.25 per share.

Arrowhead has received a $500 million upfront payment in addition to $325 million through Sarepta’s purchase of Arrowhead common stock at $27.25 per share. Over the next five years, Arrowhead is set ...